BioTime to present OpRegen® Phase I/IIa study outcomes at ARVO 2019
Category: #health  By Nikita Chaurasia  Date: 2019-04-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

BioTime to present OpRegen® Phase I/IIa study outcomes at ARVO 2019

BioTime Incorporation, a clinical stage biotechnology firm developing newfangled cellular treatments, has recently declared that updated outcomes from a Phase I/IIa clinical study of OpRegen®, its chief product candidate, would be presented at the ARVO 2019 event, scheduled between April 28 & May 2, 2019, in Vancouver, BC, Canada.

For the record, OpRegen® is a RPE (retinal pigment epithelium) cell transplant therapy presently under development for the cure of dry AMD (age-related macular degeneration) with geographic atrophy.

Reportedly, the abstract presentation will be provided within the session of the Advances in Retinal Gene Therapy & Stem Cells between 10:15 AM - 12:00 PM EDT on 2nd May 2019 by Professor of Ophthalmology at Hadassah-Hebrew University Medical Center Dr. Eyal Banin, MD, Ph. D.

According to sources familiar with the development, the abstract will offer insights into updated data from patient associates one through three of the clinical study and newfangled data from the ongoing patient associate four in better vision patients.

According to a press release by BioTime, the preclinical outcomes of BioTime’s Vision Restoration Program will also be presented. VRP is firm’s patented research program targeting the development of technology which allows the creation of 3D human retinal tissue attained from human pluripotent cells.

The 3D retinal tissue technology of BoiTime is being developed to accurately address an array of serious retinal degenerative diseases (for example: retinitis pigmentosa or advanced type of AMD) by utilizing retinal tissue restoration process, reported sources with the knowledge of the technology.

In 2017, the National Institutes of Health’s Small Business Innovation Research program reportedly provided BioTime a funding of up to $1.56 Mn to further grow this next generation, innovative vision restoration program.

For the uninitiated, BioTime is a clinical stage biotechnology firm involved in the development of several new cellular therapies focused on degenerative retinal disorders, neurological diseases linked with demyelination, and abetting the human body in combating and detecting cancer.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Japan’s SoftBank amid plans to invest in venture capital funds
Japan’s SoftBank amid plans to invest in venture capital funds
By Nikita Chaurasia

The conglomerate plans to mark its presence in Latin America by investing in venture capital funds, with a strategy to deploy nearly $500 million in five to 10 funds. SoftBank Group Corp., a multinational conglomerate based out of Tokyo, reportedly ...

TG Manufacturing acquires contract manufacturing firm TurnKey
TG Manufacturing acquires contract manufacturing firm TurnKey
By Nikita Chaurasia

TurnKey presently supplies a varied group of consumers in the industrial laboratory, defense and gaming industries among others. Using TGM’s advanced manufacturing technology, quality systems and global network and combining them with TurnKe...

Oxurion concludes enrollment of patients for THR-687 Phase 1 trial
Oxurion concludes enrollment of patients for THR-687 Phase 1 trial
By Nikita Chaurasia

12 patients with DME have enrolled into the study.   The results for the Phase 1 trial will be out by the end of 2019. Oxurion NV, a biopharmaceutical firm involved in the development of innovative treatments to preserve vision of diabetic...